AMGEN INC Annual Report, Year Ended Dec 31, 2007

Amgen Inc.'s 2007 10-K filing highlights a challenging year dominated by significant regulatory and reimbursement headwinds impacting its erythropoiesis-stimulating agent (ESA) products, Aranesp® and EPOGEN®. These challenges, stemming from observed adverse safety results in various studies and subsequent label updates and coverage restrictions by regulatory bodies like the FDA and CMS, led to a substantial reduction in ESA revenues, particularly Aranesp® sales in the U.S. supportive cancer care segment. In response, Amgen initiated a significant restructuring plan, involving staff reductions and operational rationalization, expecting charges of $775 million to $825 million. Despite these setbacks, Amgen reported notable accomplishments, including a successful defense of its intellectual property related to erythropoietin patents against Roche and continued advancement of its pipeline, with positive developments in its denosumab and Nplate™ programs. Strategic collaborations and acquisitions, such as those with Daiichi Sankyo and Takeda, as well as the acquisitions of Alantos and Ilypsa, underscore Amgen's commitment to expanding its R&D capabilities and product pipeline. The company's overall revenues saw a modest increase, driven by strong performance in ENBREL and Neulasta®, though this was substantially offset by the decline in Aranesp® sales. Investors should closely monitor the ongoing impact of regulatory changes, reimbursement policies, and pipeline progress for Amgen's future performance.